Stephan Oehen

Chief Operating Officer and Founder

Immunologist, PhD with 21 years experience in biotech and pharma, a strong science (University Basel, University Hospital Zürich, UC San Diego), and drug development background in Autoimmunity, Transplantation and Inflammation (ATI). Stephan has an expert track record in Program Management and held several leadership positions in biotech (Cytos Biotechnology) and big pharma (Novartis Pharma). In 2006 he joined Novartis Research (NIBR) holding positions as Project Management Director ATI and Therapeutic Area Head of the Project Management Office. In his roles he managed the KRP203 program from inception to today. In 2018, he moved to Novartis Global Drug Development (Global Health) as Global Program Director (GPD) for out-partnering and as GPD of the Transplant Global Program Team.